Juggling Between The Cost And Value of New Therapies: Does Science Still Serve Patient Needs?

In the aftermath of the withdrawal of Zynteglo, the first gene therapy for patients with β-thalassaemia, from Europe, TIF´s Executive Director, Dr Androulla Eleftheriou, reflects on the viability of the EU and other markets for innovative -and often costly- curative treatments for patients, such as gene and cell therapies, and highlights key considerations for future challenges in the field.

Juggling between the Cost and Value of New Therapies_ FINAL

Download the Article